(Q39647813)

13 September 2017

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer (English)

1 reference

13 September 2017

phase II clinical trial

0 references

1 reference

L H Jensen

1

1 reference

13 September 2017

J Lindebjerg

2

1 reference

13 September 2017

J Ploen

3

1 reference

13 September 2017

T F Hansen

4

1 reference

13 September 2017

A Jakobsen

5

1 reference

13 September 2017

language of work or name

1 reference

23 February 2012

1 reference

13 September 2017

1 reference

13 September 2017

23

1 reference

13 September 2017

9

1 reference

13 September 2017

2341-2346

1 reference

13 September 2017

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Cholangiocarcinoma: update and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS008

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS008

1 reference

13 September 2017

1 reference